The FDA Slaps Major Warning About Pfizer Drug as Vaccine Reactions Come Under Scrutiny
by Kyle Becker
The FDA has recently admitted there is now major concern over another Pfizer product. It is now slapping a warning on a class of anti-inflammatory treatments called JAK inhibitors.
“The U.S. health regulator has added its strictest warning to the labels of drugs from Pfizer, Eli Lilly and AbbVie belonging to a class of anti-inflammatory treatments called JAK inhibitors, citing risk of serious health issues and death in patients 50 and over,” Reuters reported on Friday, citing the drug manufacturers.
“The addition of the warning on the labels follows the agency’s review of Pfizer’s Xeljanz after initial results from a February trial showed an increased risk of serious heart-related problems and cancer in some patients being treated with the drug,” the report added.
The alarming development is a reminder of the rushed approval of Pfizer’s “vaccine.” In June, the COVID-19 Vaccine Safety Technical (VaST) Work Group noted the adverse reaction in vaccinated males between the ages of 16 and 24. The development of the heart condition was observed in adolescents and young adults and was considerably higher after the second dose in males.
Rep. Thomas Massie noted that the Expected and Observed categories in VAERS diverged dramatically for Myocarditis and Pericarditis in the age groups ranging from 12 to 49.
more
https://trendingpolitics.com/the-fda-slaps-major-warning-about-pfizer-drug-as-vaccine-reactions-come-under-scrutiny-knab/
